Concurrent with the clinical review, our financial team solicits and negotiates supplemental rebate offers from pharmaceutical manufacturers with drug products in the therapeutic drug classes being reviewed. Magellan Rx facilitates supplemental rebate agreement execution with pharmaceutical manufacturers on behalf of our state customers. These agreements include guaranteed net unit prices and may contain additional language describing state actions (e.g. clinical criteria, step-edits) that are permissible for continued supplemental rebate eligibility. Financial analysis for all PDL classes details the impact of various rebates on net pricing to the state regardless of preferred or non-preferred status.